These two authors have contributed equally to this work.
Letter to the Editor
Bioactive tetrapeptide GEKG boosts extracellular matrix formation: in vitro and in vivo molecular and clinical proof
Article first published online: 22 JUN 2011
© 2011 John Wiley & Sons A/S
Volume 20, Issue 7, pages 602–604, July 2011
How to Cite
Farwick, M., Grether-Beck, S., Marini, A., Maczkiewitz, U., Lange, J., Köhler, T., Lersch, P., Falla, T., Felsner, I., Brenden, H., Jaenicke, T., Franke, S. and Krutmann, J. (2011), Bioactive tetrapeptide GEKG boosts extracellular matrix formation: in vitro and in vivo molecular and clinical proof. Experimental Dermatology, 20: 602–604. doi: 10.1111/j.1600-0625.2011.01307.x
- Issue published online: 22 JUN 2011
- Article first published online: 22 JUN 2011
- Accepted for publication 15 April 2011
Abstract: The ‘matrikine’ concept claims that processing of the precursors for collagen results in the formation of peptides such as KTTKS which in turn augments extracellular matrix (ECM) production. In the present study, we show the development of an anti-ageing active from an in silico approach by molecular design resulting in the tetrapeptide GEKG derived from ECM proteins. The efficacy of the peptide to significantly induce collagen production of the protein level and mRNA level has been demonstrated in vitro in human dermal fibroblasts and in vivo in a double-blind, randomized, placebo-controlled study enroling 10 volunteers with an average age of 48.2 years. The effect of GEKG on facial wrinkles was studied in 30 volunteers using state of the art fringe projection, which allows determination of surface roughness in three-dimensions. Here, only GEKG but not the placebo was able to significantly decrease skin roughness as a measure for wrinkles.